Abciximab

Cat. No.:	HY-P9934
CAS No.:	143653-53-6
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1].
In Vitro	Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet $\alpha_{IIb}\beta_3$ integrin[2]. Abciximab appears to have similar affinity for the $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ integrins and redistributes between them[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats weighing 200-250 g, balloon angioplasty model[2]
Dosage:	0.25 mg/kg/day
Administration:	Intravenous injection, 28 days
Result:	Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB_2 concentration.

REFERENCES

[1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.

[2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA